Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.

Product Highlight - Invokana

16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
  • INVOKANA demonstrated statistically significant glycated haemoglobin A1c (HbA1c) reductions and helped more patients achieve the ADA-recommended HbA1c goal of <7%1,4.
  • Only Invokana 300 mg demonstrated greater reductions in vs HbA1c sitagliptin 100 mg2.
  • INVOKANA results in the excretion of approximately 77 grams to 119 grams of glucose per day3.
  • INVOKANA provided greater reductions in body weight and systolic blood pressure vs placebo3.
  • INVOKANA showed good tolerability profile with the following most common adverse reactions – female genital mycotic infection, urinary tract infection (UTI) and increased urination3.
References:
1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab.2013;15(4):372-382.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
3. Invokana_Approved Prescribing Information_Malaysia_EU SmPC vJan2016.
4: American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Supplement 1): S39-S46.

Further information is available in Section 11b, New In This Issue and mims.com
Full prescribing information is available upon request.

MKT-CAN-MY-0026Creation Date: October 2016

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.